BrainsWay Ltd. BWAY · NASDAQ
$11.98 -0.42% (-$0.05)
Summary
61 / 100 · Bulios Score
What speaks for it
- Revenue grew by 24% a year over the last 3 years.
- Out of every 100 USD of revenue, 16 USD is left as net profit.
- It holds more cash than debt: $62.4M against $7.13M.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 49.4 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 24% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 25 USD
- Research and development 18 USD
- Sales and administration 45 USD
- Taxes and other -3.2 USD
- Net profit 16 USD
Net profit, industry median (Medical - Specialties) 7.5 USD
Out of every 100 USD of revenue, 16 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.3 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $19.5 is 63% above today's price. 88% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
The company reports no revenue by product.
By region
- Other 100%
Other brings in 100% of revenue.
Segments in detail